scispace - formally typeset
Open AccessJournal ArticleDOI

Letter to the editor.

Alpo Vuorio, +2 more
- 17 Aug 2022 - 
- Vol. 75, Iss: 12, pp 2281-2282
Reads0
Chats0
About
This article is published in Clinical Infectious Diseases.The article was published on 2022-08-17 and is currently open access. It has received 5 citations till now. The article focuses on the topics: Medicine & Betacoronavirus.

read more

Citations
More filters
Journal ArticleDOI

Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19

TL;DR: In this paper , the authors found that patients with heterozygous familial hypercholesterolemia (HeFH) are at increased risk for COVID-19 cardiovascular complications in the acute phase of the infection.
Journal ArticleDOI

Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19

TL;DR: In this paper , the authors found that patients with heterozygous familial hypercholesterolemia (HeFH) are at increased risk for COVID-19 cardiovascular complications in the acute phase of the infection.
Journal ArticleDOI

Angiotensin II constricts mouse iliac arteries: possible mechanism for aortic aneurysms.

TL;DR: In this paper , an isometric tension analysis was conducted on 18-week-old male C57BL/6 mice (n = 4) brachiocephalic arteries (BC), iliac arteries (IL), and abdominal (AA) and thoracic aorta (TA).
References
More filters
Journal ArticleDOI

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

TL;DR: Authors/Task Force Members (François Macha, Colin Baigentb,∗∗,2, Alberico L. Catapanoc), ESC Committee for Practice Guidelines (CPG) (Stephan Windeckeraa), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Patelcl)
Journal ArticleDOI

Statins and the Covid-19 main protease: In silico evidence on direct interaction

TL;DR: Results indicate that statins could be efficient SARS-CoV-2 Mpro inhibitors, based upon the binding energy of pitavastatin, rosuvastsatin, lovastatin and fluvastatin; however, further research is necessary to investigate their potential use as drugs for COVID-19.
Journal ArticleDOI

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

TL;DR: Paxlovid appears to be more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease and in real-life settings, Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality.
Related Papers (5)